Download presentation
Presentation is loading. Please wait.
1
Drug Design Optimizing Target Interactions
Chapter 13 Part 3
2
1. Drug design - optimizing binding interactions
Aim - To optimize binding interactions with target Reasons To increase activity and reduce dose levels To increase selectivity and reduce side effects Strategies Vary alkyl substituents Vary aryl substituents Extension Chain extensions / contractions Ring expansions / contractions Ring variation Isosteres Simplification Rigidification
3
2. Vary alkyl substituents
Rationale: Alkyl group in lead compound may interact with hydrophobic region in binding site Vary length and bulk of group to optimise interaction
4
2. Vary alkyl substituents
Rationale: Vary length and bulk of alkyl group to introduce selectivity Binding region for N Receptor 1 Receptor 2
5
2. Vary alkyl substituents
Rationale: Vary length and bulk of alkyl group to introduce selectivity Example: Selectivity of adrenergic agents for b-adrenoceptors over a-adrenoceptors
6
2. Vary alkyl substituents
Adrenaline Salbutamol (Ventolin) (Anti-asthmatic) Propranolol (b-Blocker)
7
a-Adrenoceptor H-Bonding region Ionic bonding Van der Waals
8
a-Adrenoceptor ADRENALINE
9
a-Adrenoceptor
10
b-Adrenoceptor ADRENALINE
11
b-Adrenoceptor SALBUTAMOL
12
b-Adrenoceptor
13
a-Adrenoceptor SALBUTAMOL
14
a-Adrenoceptor SALBUTAMOL
15
a-Adrenoceptor SALBUTAMOL
16
a-Adrenoceptor SALBUTAMOL
17
a-Adrenoceptor SALBUTAMOL
18
a-Adrenoceptor SALBUTAMOL
19
a-Adrenoceptor SALBUTAMOL
20
a-Adrenoceptor
21
2. Vary alkyl substituents
Synthetic feasibility of analogues Feasible to replace alkyl substituents on heteroatoms with other alkyl substituents Difficult to modify alkyl substituents on the carbon skeleton of a lead compound.
22
2. Vary alkyl substituents
Methods
23
2. Vary alkyl substituents
Methods
24
3. Vary aryl substituents
Vary substituents Vary substitution pattern Weak H-Bond Binding Region (H-Bond) (for Y) Strong H-Bond (increased activity)
25
3. Vary aryl substituents
Vary substituents Vary substitution pattern Benzopyrans Anti-arrhythmic activity best when substituent is at 7-position
26
Inductive electron withdrawing effect
3. Vary aryl substituents Vary substituents Vary substitution pattern Para substitution: Electron withdrawing effect due to resonance + inductive effects leading to a weaker base Meta substitution: Inductive electron withdrawing effect Notes Binding strength of NH2 as HBD affected by relative position of NO2 Stronger when NO2 is at para position
27
4. Extension - extra functional groups
Rationale: To explore target binding site for further binding regions to achieve additional binding interactions RECEPTOR RECEPTOR Extra functional group Unused binding region DRUG DRUG Drug Extension Binding regions Binding group
28
4. Extension - extra functional groups
Example: ACE Inhibitors Hydrophobic pocket Vacant EXTENSION Hydrophobic pocket Binding site Binding site
29
4. Extension - extra functional groups
Example: Nerve gases and medicines Sarin (nerve gas) Ecothiopate (medicine) Notes: Extension - addition of quaternary nitrogen Extra ionic bonding interaction Increased selectivity for cholinergic receptor Mimics quaternary nitrogen of acetylcholine Acetylcholine
30
4. Extension - extra functional groups
Example: Second-generation anti-impotence drugs Viagra Notes: Extension - addition of pyridine ring Extra van der Waals interactions and HBA Increased target selectivity
31
4. Extension - extra functional groups
Example: Antagonists from agonists Propranolol (b-Blocker) Adrenaline Cimetidine (Tagamet) (Anti-ulcer) Histamine
32
5. Chain extension / contraction
Rationale: Useful if a chain is present connecting two binding groups Vary length of chain to optimise interactions Weak interaction Strong interaction A B Chain extension A B RECEPTOR RECEPTOR Binding regions Binding groups A & B
33
5. Chain extension / contraction
Example: N-Phenethylmorphine Binding group Optimum chain length = 2
34
Better overlap with hydrophobic interactions
6. Ring expansion / contraction Rationale: To improve overlap of binding groups with their binding regions R Ring expansion R Better overlap with hydrophobic interactions Hydrophobic regions
35
Carboxylate ion out of range
6. Ring expansion / contraction Vary n to vary ring size Example: Binding regions Binding site Binding site Two interactions Carboxylate ion out of range Three interactions Increased binding
36
7. Ring variations Rationale:
Replace aromatic/heterocyclic rings with other ring systems Often done for patent reasons General structure for NSAIDS Core scaffold
37
7. Ring variations Rationale: Sometimes results in improved properties
Example: UK-46245 Improved selectivity Ring variation Structure I (Antifungal agent) UK-46245 Improved selectivity Ring variation Structure I (Antifungal agent)
38
7. Ring variations Example - Nevirapine (antiviral agent) Additional
binding group
39
Selective for b-adrenoceptors over a-adrenoreceptors
7. Ring variations Example - Pronethalol (b-blocker) Selective for b-adrenoceptors over a-adrenoreceptors
40
8. Isosteres and bio-isosteres
Rationale for isosteres: Replace a functional group with a group of same valency (isostere) e.g. OH replaced by SH, NH2, CH3 O replaced by S, NH, CH2 Leads to more controlled changes in steric / electronic properties May affect binding and / or stability
41
8. Isosteres and bio-isosteres
Useful for SAR Propranolol (b-blocker) Propranolol (b-blocker) Notes Replacing OCH2 with CH=CH, SCH2, CH2CH2 eliminates activity Replacing OCH2 with NHCH2 retains activity Implies O involved in binding (HBA)
42
8. Isosteres and bio-isosteres
Rationale for bio-isosteres: Replace a functional group with another group which retains the same biological activity Not necessarily the same valency Example: Antipsychotics Sultopride DU DU Pyrrole ring = bio-isostere for amide group Improved selectivity for D3 receptor over D2 receptor
43
9. Simplification Rationale:
Lead compounds from natural sources are often complex and difficult to synthesize Simplifying the molecule makes the synthesis of analogues easier, quicker and cheaper Simpler structures may fit the binding site better and increase activity Simpler structures may be more selective and less toxic if excess functional groups are removed
44
9. Simplification Methods: Retain pharmacophore
Remove unnecessary functional groups
45
9. Simplification Methods: Remove excess rings Example:
Excess functional groups Excess ring
46
9. Simplification Methods: Remove asymmetric center Asymmetric center
47
9. Simplification Methods:
Simplify in stages to avoid oversimplification Pharmacophore Notes: Simplification does not mean ‘pruning groups’ off the lead compound Compounds usually made by total synthesis
48
INT104
49
INT104
50
INT104
51
INT104
52
INT104
53
9. Simplification Example: Important binding groups retained
Pharmacophore Important binding groups retained Unnecessary ester removed Complex ring system removed
54
9. Simplification Disadvantages:
Oversimplification may result in decreased activity and selectivity Simpler molecules have more conformations More likely to interact with more than one target binding site May result in increased side effects
55
INT115 Target binding site
56
INT116 Target binding site
57
Rotatable bonds INT116 Target binding site
58
Rotatable bonds INT116 Target binding site
59
Rotatable bonds INT116 Target binding site
60
Rotatable bonds INT116 Target binding site
61
Rotatable bonds INT116 Target binding site
62
Rotatable bonds INT116 Target binding site
63
Rotatable bonds INT116 Target binding site
64
Rotatable bonds INT116 Target binding site
65
Rotatable bonds INT116 Target binding site
66
Rotatable bonds INT116 Target binding site
67
Rotatable bonds INT117 Target binding site
68
Rotatable bonds INT118 Different binding site leading to side effects
69
9. Simplification Oversimplification of opioids
70
MORPHINE C C O C C C C MOR062.WAV N SIMPLIFICATION
71
LEVORPHANOL C C O C C C C MOR064.WAV N SIMPLIFICATION
72
LEVORPHANOL C C O C C C C MOR064.WAV N SIMPLIFICATION
73
METAZOCINE C C O C C C C MOR065.WAV N SIMPLIFICATION
74
C C O C C C C MOR065.WAV N OVERSIMPLIFICATION
75
TYRAMINE C C O C C C C MOR065.WAV N OVERSIMPLIFICATION
76
AMPHETAMINE C C O C C C C MOR065.WAV N OVERSIMPLIFICATION
77
10. Rigidification Note Endogenous lead compounds are often simple and flexible Fit several targets due to different active conformations Results in side effects Strategy Rigidify molecule to limit conformations - conformational restraint Increases activity - more chance of desired active conformation being present Increases selectivity - less chance of undesired active conformations Disadvantage Molecule is more complex and may be more difficult to synthesise
78
10. Rigidification RECEPTOR 2 RECEPTOR 1
79
10. Rigidification Methods - Introduce rings
Bonds within ring systems are locked and cannot rotate freely Test rigid structures to see which ones have retained active conformation
80
10. Rigidification Methods - Introduce rings
Bonds within ring systems are locked and cannot rotate freely Test rigid structures to see which ones have retained active conformation
81
10. Rigidification Methods - Introduce rings
Bonds within ring systems are locked and cannot rotate freely Test rigid structures to see which ones have retained active conformation Rigidification Rotatable bonds
82
Rotatable bond INT119
83
Rotatable bond Ring formation INT120
84
Ring formation INT120
85
10. Rigidification Methods - Introduce rigid functional groups
86
10. Rigidification Analogues Examples Inhibits platelet aggregation
Important binding groups Inhibits platelet aggregation Analogues Rigid Rigid
87
10. Rigidification Examples - Combretastatin (anticancer agent)
Rotatable bond Less active More active
88
10. Rigidification Methods - Steric Blockers Introduce steric block
Flexible side chain Introduce steric block Orthogonal rings preferred Coplanarity allowed
89
10. Rigidification Methods - Steric Blockers Serotonin antagonist
Introduce methyl group Steric clash Increase in activity Active conformation retained
90
10. Rigidification D3 Antagonist Methods – Steric Blockers
Steric clash D3 Antagonist Inactive - active conformation disallowed
91
N CH HN O 3 10. Rigidification
Identification of an active conformation by rigidification N CH 3 HN O
92
N N CH N HN O 3 10. Rigidification
Identification of an active conformation by rigidification N N CH 3 N HN O
93
N N CH N HN O 3 10. Rigidification
Identification of an active conformation by rigidification N N CH 3 N HN O
94
N N CH N HN O 3 10. Rigidification
Identification of an active conformation by rigidification N N CH 3 N HN O
95
N N CH N HN O 3 10. Rigidification
Identification of an active conformation by rigidification N N CH 3 N HN O
96
N N CH N HN O 3 10. Rigidification
Identification of an active conformation by rigidification N N CH 3 N HN O
97
N N CH N HN O 3 10. Rigidification
Identification of an active conformation by rigidification N N CH 3 N HN O
98
10. Rigidification Planar conformation
Identification of an active conformation by rigidification Planar conformation
99
10. Rigidification Orthogonal conformation
Identification of an active conformation by rigidification Orthogonal conformation
100
10. Rigidification Identification of an active conformation by rigidification CYCLISATION
101
10. Rigidification Identification of an active conformation by rigidification CYCLISATION
102
10. Rigidification Locked into planar conformation
Identification of an active conformation by rigidification CYCLISATION Locked into planar conformation
103
10. Rigidification Identification of an active conformation by rigidification STERIC HINDRANCE
104
10. Rigidification Identification of an active conformation by rigidification STERIC HINDRANCE
105
10. Rigidification Identification of an active conformation by rigidification STERIC HINDRANCE
106
10. Rigidification Identification of an active conformation by rigidification STERIC HINDRANCE
107
10. Rigidification Locked into orthogonal conformation
Identification of an active conformation by rigidification STERIC HINDRANCE Locked into orthogonal conformation
108
11. Structure-based drug design
Strategy Carry out drug design based on the interactions between the lead compound and the target binding site Procedure Crystallize target protein with bound ligand Acquire structure by X-ray crystallography Download to computer for molecular modelling studies Identify the binding site Identify the binding interactions between ligand and target Identify vacant regions for extra binding interactions Remove the ligand from the binding site in silico ‘Fit’ analogues into the binding site in silico to test binding capability Identify the most promising analogues Synthesise and test for activity Crystallise a promising analogue with the target protein and repeat the process
111
INT024
112
INT024
113
INT024
114
INT024
115
INT024
116
INT024
117
INT024
118
INT024
119
INT024
120
INT024
121
INT024
122
12. De Novo Drug Design The design of novel agents based on a knowledge of the target binding site Procedure Crystallise target protein with bound ligand Acquire structure by X-ray crystallography Download to computer for molecular modelling studies Identify the binding site Remove the ligand in silico Identify potential binding regions in the binding site Design a lead compound to interact with the binding site Synthesise the lead compound and test it for activity Crystallise the lead compound with the target protein and identify the actual binding interactions Optimise by structure-based drug design
Similar presentations
